1. Home
  2. ECOR vs IFRX Comparison

ECOR vs IFRX Comparison

Compare ECOR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo electroCore Inc.

ECOR

electroCore Inc.

HOLD

Current Price

$10.20

Market Cap

81.0M

Sector

Health Care

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.63

Market Cap

66.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECOR
IFRX
Founded
2005
2007
Country
United States
Germany
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.0M
66.0M
IPO Year
2018
2017

Fundamental Metrics

Financial Performance
Metric
ECOR
IFRX
Price
$10.20
$1.63
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$18.00
$6.25
AVG Volume (30 Days)
171.3K
1.2M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$32,032,000.00
N/A
Revenue This Year
$33.60
N/A
Revenue Next Year
$30.40
N/A
P/E Ratio
N/A
N/A
Revenue Growth
27.20
N/A
52 Week Low
$4.16
$0.74
52 Week High
$10.40
$2.95

Technical Indicators

Market Signals
Indicator
ECOR
IFRX
Relative Strength Index (RSI) 65.94 34.76
Support Level $4.92 $1.15
Resistance Level $10.37 $1.82
Average True Range (ATR) 1.16 0.17
MACD 0.08 -0.11
Stochastic Oscillator 93.88 5.78

Price Performance

Historical Comparison
ECOR
IFRX

About ECOR electroCore Inc.

electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: